Nakaya N, Homma Y, Tamachi H, Goto Y
Atherosclerosis. 1986 Aug;61(2):125-8. doi: 10.1016/0021-9150(86)90071-7.
CS-514 is a competitive inhibitor of HMG-CoA reductase. The effect of this agent on serum lipids and lipoproteins was studied in 10 healthy normocholesterolemic male volunteers by giving 20 mg of CS-514 or placebo twice a day for 7 days under double-blind conditions. The mean total serum cholesterol level decreased by 18.6% in the CS-514 group, whereas it increased by 7.4% in the placebo group and the difference between the two groups was statistically significant (P less than 0.01). LDL cholesterol and LDL apo B values were reduced by 22.6% and 23.2%, respectively. Serum triglyceride level did not change significantly. No clinical or laboratory abnormalities were observed.
CS - 514是HMG - CoA还原酶的竞争性抑制剂。在10名健康的正常胆固醇水平男性志愿者中,通过在双盲条件下每天两次给予20毫克CS - 514或安慰剂,持续7天,研究了该药物对血清脂质和脂蛋白的影响。CS - 514组的平均总血清胆固醇水平下降了18.6%,而安慰剂组则上升了7.4%,两组之间的差异具有统计学意义(P小于0.01)。低密度脂蛋白胆固醇和低密度脂蛋白载脂蛋白B值分别降低了22.6%和23.2%。血清甘油三酯水平没有显著变化。未观察到临床或实验室异常情况。